Therapeutic Drug Market for Acne

Content

• 1. Overview
  • 1.1 Statement of Report
  • 1.2 About This Report
  • 1.3 Scope of the Report
  • 1.4 Objectives
  • 1.5 Methodology
  • 1.6 Executive Summary
• 2. Introduction to Cancer Biology and the Diagnostic Industry
  • 2.1 Cancer
    • 2.1.1 The Disease
    • 2.1.2 Metastasis
    • 2.1.3 Demographics and Statistics of Cancer
  • 2.2 The Drivers of the Biotech and Diagnostics Industry
    • 2.2.1 Technological Innovation
    • 2.2.2 Government Funding
    • 2.2.3 Pharmaceutical Development
  • 2.3 Outlook for Tumor Markers
• 3. Tumor Markers Market Segment Analysis: Size, Growth and Share
  • 3.1 Market Description
  • 3.2 Clinical Diagnostic Serum Based Cancer Markers
  • 3.3 PSA Testing Market Size
  • 3.4 DNA Markers
  • 3.5 Serum proteins
  • 3.6 Enzymes
  • 3.7 Occult Blood
  • 3.8 Histology and In Situ Hybridization (ISH)
  • 3.9 Cervical Cytology
  • 3.10 Immunohistochemistry
  • 3.11 In Vivo Detection Cancer Products
  • 3.12 Radionuclides and X-Ray Detection Products
  • 3.13 Human Papillomavirus (HPV) Testing
  • 3.14 Bladder Cancer Testing
• 4. Diagnostic Methods for Cancer Detection
  • 4.1 Organ Specific Tumor Markers
    • 4.1.1 Colon Cancer
    • 4.1.2 Prostate Cancer
    • 4.1.3 Pancreatic Cancer
    • 4.1.4 Breast Cancer
    • 4.1.5 Ovarian Cancer
    • 4.1.6 Cervical Cancer
    • 4.1.7 Lung Cancer
    • 4.1.8 Testicular Cancer
    • 4.1.9 Bladder Cancer
    • 4.1.10 Hepatic Cancer
    • 4.1.11 Stomach Cancer
    • 4.1.12 Malignant Melanoma
    • 4.1.13 Acute Myeloid Leukemia (AML) and Acute Lymphoblastoid Leukaemia (ALL)
    • 4.1.14 Lymphoma
  • 4.2 Clinical Laboratory Methods for Measuring Tumor Markers
    • 4.2.1 Abbott Diagnostics AxSYM
    • 4.2.2 Roche Diagnostics Elecsys
    • 4.2.3 Beckman Coulter Diagnostics Access
    • 4.2.4 Bayer Diagnostics ADVIA Centaur
    • 4.2.5 Dade Diagnostics Stratus
    • 4.2.6 Diagnostic Products Corporation Immulite
    • 4.2.7 Tosoh Medics A1A
    • 4.2.8 CIS bio International Kryptor
    • 4.2.9 Ortho-Clinical DiagnosticsVitros ECiQ
    • 4.2.10 Fujirebio Diagnostics
    • 4.2.11 bioMrieux Vidas
    • 4.2.12 Eisai Picolumi
    • 4.2.13 TOSOH Medics
  • 4.3 New Technologies for Cancer Diagnostics
    • 4.3.1 New and Improved Immunoassays
    • 4.3.2 Immunohistochemical Tests
    • 4.3.3 Molecular (DNA and Genomic) Diagnostic Assays
    • 4.3.4 Genomics and Genetic Markers
    • 4.3.5 Proteomics and New Protein Markers
      • 4.3.5.1 Inside the ProteinChip System
      • 4.3.5.2 Rapid Biological Assays on a Chip
      • 4.3.5.3 Proteome Pattern Recognition
    • 4.3.6 New Platform Technologies Including Flow Cytometry
    • 4.3.7 Stem Cell Markers
    • 4.3.8 Monoclonal Antibodies
    • 4.3.9 Proteomics and Cancer Antibodies
    • 4.3.10 Pharmacogenomics and Oncology Diagnostics
    • 4.3.11 DNA Microarrays
    • 4.3.12 Future Directions
  • 4.4 Clinical Methods for Diagnosis of Cancer
    • 4.4.1 Screening
    • 4.4.2 Sigmoidoscopy
    • 4.4.3 Imaging
    • 4.4.4 Theranostics
• 5. Implications of Molecular Biology for New Diagnostic Cancer Tests
• 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms
  • 6.1 Abbott Diagnostics
  • 6.2 Affymetrix
  • 6.3 Agensys
  • 6.4 AMDL
  • 6.5 Arcturus Applied Genomics
  • 6.6 Aureon Biosciences
  • 6.7 Bard Diagnostics
  • 6.8 Bayer Diagnostics
  • 6.9 Beckman Coulter
  • 6.10 Biocode S.A.
  • 6.11 BioCurex
  • 6.12 Biomedical Diagnostics
  • 6.13 Biomerica
  • 6.14 bioMrieux
  • 6.15 Biomira
  • 6.16 BioModa
  • 6.17 Bruker Daltonics
  • 6.18 Byk Gulden
  • 6.19 Ciphergen Biosystems, Inc.
  • 6.20 Clarient, Inc.
  • 6.21 Correlogic Systems
  • 6.22 Cytogen
  • 6.23 Cytyc Corp.
  • 6.24 DiaDexus LLC
  • 6.25 Digene Corporation
  • 6.26 DiagnoCure
  • 6.27 Diagnostic Products Corporation
  • 6.28 Diagnostic Systems Laboratories Inc.
  • 6.29 DRG International
  • 6.30 Eisai Co., Ltd.
  • 6.31 Epigenomics
  • 6.32 Exact Sciences Corporation
  • 6.33 Gene Logic
  • 6.34 Genomic Health
  • 6.35 Geron Corporation
  • 6.36 Immunicon
  • 6.37 Immunomedics
  • 6.38 Incyte Pharmaceuticals
  • 6.39 LabCorp
  • 6.40 Matritech
  • 6.41 Mitsubishi Kagaku Medical
  • 6.42 Molecular Diagnostics, Inc.
  • 6.43 Myriad Genetics
  • 6.44 NeoRx Corp.
  • 6.45 Nexell Therapeutics
  • 6.46 Northwest Biotherapeutics, Inc.
  • 6.47 Nuvelo
  • 6.48 Oncotech, Inc.
  • 6.49 Polymedco
  • 6.50 Princeton BioMeditech Corporation
  • 6.51 Procyon BioPharma, Inc.
  • 6.52 Qiagen
  • 6.53 Sanko Junyaku Co., Ltd.
  • 6.54 Tosoh Medics
  • 6.55 TriPath Imaging
  • 6.56 UroCor, Inc.
  • 6.57 Ventana Medical Systems
  • 6.58 Veridex
  • 6.59 Worldwide Medical Corporation
• 7. Business Trends in the Industry
  • 7.1 Industry Consolidation
  • 7.2 Breath of Product Offering and Pricing
  • 7.3 Government Regulation of Medical Devices
  • 7.4 Strategic Business and Marketing Considerations
  • 7.5 Commercial Opportunities in Cancer Markers
  • 7.6 Moderators of Growth
  • 7.7 Biotechnology Industry Trends
  • 7.8 Pharmaceutical Industry Trends
  • 7.9 Acquisition, License Agreement, Partnerships
  • 7.10 Legal Developments
  • 7.11 Sales and Marketing Strategies for Tumor Marker Tests
    • 7.11.1 North American Market
    • 7.11.2 International Markets
      • 7.11.2.1 Europe
      • 7.11.2.2 Central and South America
      • 7.11.2.3 Asia/Pacific
• 8. Tumor Marker Testing: Important Issues
  • 8.1 Trends in Patient Care and Reimbursement
  • 8.2 Trends in Reimbursement Practice
  • 8.3 Clinical Laboratory Improvement Act (CLIA)
  • 8.4 Unmet Needs in Tumor Markers
• 9. Important New Technology Areas
  • 9.1 Proteomics
  • 9.2 DNA Sequencing
  • 9.3 The Human Genome Project
  • 9.4 Liquid Phase Chromatography
  • 9.5 Polymerase Chain Reaction (PCR)
  • 9.6 Capillary Electrophoresis
  • 9.7 Proteomics
  • 9.8 Use of Mass Spectroscopy in Sequencing
  • 9.9 High-Throughput Organic Synthesis
• 10. New Cancer Markers in Basic Research
  • 10.1 Genetics of Cancer
  • 10.2 Telomerase
  • 10.3 Stomach Cancer
  • 10.4 Head and Neck Cancer
  • 10.5 Breast Cancer
  • 10.6 Prostate Cancer: p27 (kip1) A New Molecular Marker For Prostate Cancer
  • 10.7 PSMA
  • 10.8 Cervical Cancer: NMPI79
  • 10.9 Pancreatic Cancer: Peritoneal Cytology
  • 10.10 Colorectal Cancer: CEA Doubling Time
  • 10.11 Uterine and Kidney Cancer: MN/CA9
  • 10.12 MMSC1 Scaffold Gene
  • 10.13 p16 Tumor Suppressor Gene
  • 10.14 MTS2 and p19 Cell Cycle Genes
  • 10.15 Complement Factor H Related Proteins
  • 10.16 MUC 2, 3, 4
  • 10.17 Cytokeratins
  • 10.18 Colon Cancer: Serum VEGF
  • 10.19 Ras Oncogenes
  • 10.20 Lung Cancer: Ribonucleoprotein A2/B1
  • 10.21 BCLA-4 Matrix Protein
  • 10.22 RAK Antigens
  • 10.23 Serum Urokinase Receptors
  • 10.24 Chips
  • 10.25 Survivin
  • 10.26 Endometrial Specific Steroid Binding Factor (hESF1)
  • 10.27 Reg-4 Protein
  • 10.28 Nox-1
  • 10.29 PSP94 Binding Protein
  • 10.30 Ettan DIGE Technology
  • 10.31 YKL-40
  • 10.32 AFP-L3
  • 10.33 DNA Methylation Technology
  • 10.34 Transthyretin and Apolipoprotein A1
  • 10.35 ADAM 12
• 11. Market Trends and Forecasts
  • 11.1 Ultrasensitive Cancer Tests
  • 11.2 Mergers and Acquisitions of Diagnostic Companies
  • 11.3 RT-PCR
  • 11.4 Genetic Tests of Hereditary Cancer Risk
  • 11.5 DNA Measurements
  • 11.6 Technical and Practical Issues for Potential New Markers
  • 11.7 Genetic Profiling
  • 11.8 Ploidy
  • 11.9 Advances in Sputum Analysis for Screening and Early Detection of Lung Cancer
  • 11.10 Pharmacogenetic Tests for Cancer
  • 11.11 Worldwide Healthcare Spending
  • 11.12 R&D Expenditures
  • Appendix 1: Web Links
  • Appendix 2: Cancer Information Resources
  • Appendix 3: Colon Cancer Staging
  • Appendix 4: Reimbursement for Tumor Marker Testing
  • Appendix 5: The Pathology of Prostate Cancer
  • Appendix 6: Government Regulation of Tumor Marker Tests
  • Appendix 7: Prevalence of Major Cancers in the U.S., 1999
  • Appendix 8: The Clinical Laboratory Improvement Act (CLIA)
  • Appendix 9: Marketers of Occult Blood Diagnostic Test Kits
• List Of Figures
  • Figure 4.1: Model of Colorectal Cancer Development
  • Figure 4.2: The BTA stat Test vs. Cytology
• List Of Tables
  • Table 2.1: Drug Development by Type of Cancer
  • Table 2.2: The 402 Organ Specific Medicines in Development for Cancer 2003
  • Table 2.3: Estimates for the Leading Sites of New Cancer Cases and Deaths in the U.S. by Sex, 2003
  • Table 2.4: Estimated Worldwide Number of New Cancer Cases and Deaths by Type of Cancer
  • Table 2.5: Estimated Number of New Cancer Cases and Deaths by Region
  • Table 2.6: Cancer Death Rates per 100,000 Population (and Rank) for All Cancer Sites by Country
  • Table 2.7: Cancer Associated Genes
  • Table 2.8: Carcinogens in the Workplace
  • Table 2.9: Private Funding Levels for the Biotechnology Segment
  • Table 2.10: Global Pharmaceutical Industry R&D Spending, 1995-2004
  • Table 2.11: U.S. Government NIH Research Budget, 1995-2004
  • Table 2.12: Herceptin Worldwide Sales, 1999-2005
  • Table 2.13: Classes of Drugs Used to Treat Breast Cancer
  • Table 3.1: In Vitro Cancer Marker Market Segments Worldwide
  • Table 3.2: Tumor Markers Currently in Common Use
  • Table 3.3: Global IVD Cancer Tumor Marker Testing Market Segments Projected Growth Rates, 2005-2010
  • Table 3.4: Worldwide Market Size in Dollar Volume for Tumor Marker Assays Product Market, 2001-2010
  • Table 3.5: U.S. Market Size in Dollar Volume for Tumor Marker Assays Product Market, 2001-2010
  • Table 3.6: Worldwide In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010
  • Table 3.7: U.S. In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010
  • Table 3.8: Japanese In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010
  • Table 3.9: European In Vitro Cancer Tumor Marker Diagnostics Market Size, 2001-2010
  • Table 3.10: Global Distribution of IVD Cancer Tumor Marker Diagnostic Testing, 2005
  • Table 3.11: Estimated Market Share of Major Competitors in U.S. Cancer Tumor Marker Diagnostics Market
  • Table 3.12: Major Presence in Cancer Tumor Marker Diagnostics Markets
  • Table 3.13: Worldwide PSA Sales, 1997-2010
  • Table 3.14: U.S. PSA Sales, 2000-2010
  • Table 3.15: Serum Markers Used Clinically
  • Table 3.16: Drivers of IHC Growth
  • Table 3.17: Digene Product Revenues and Assets
  • Table 3.18: Worldwide Bladder Cancer Marker Sales, 2001-2010
  • Table 3.19: U.S. Bladder Cancer Marker Sales, 2001-2010
  • Table 3.20: Worldwide NMP-22 Sales, 2001-2010
  • Table 4.1: Colorectal Cancer Stages
  • Table 4.2: Worldwide CEA Sales, 2001-2010
  • Table 4.3: U.S. CEA Sales, 2001-2010
  • Table 4.4: Population Statistics of Serum Levels of PSA in Men Over 50 Years of Age
  • Table 4.5: PSA Doubling Time and Time to Reach PSA of 1,000
  • Table 4.6: PSA Doubling Times
  • Table 4.7: Worldwide CA19-9 Sales, 2001-2010
  • Table 4.8: U.S. CA19-9 Sales, 2001-2010
  • Table 4.9: Worldwide CA15-3 Sales, 2001-2010
  • Table 4.10: U.S. CA15-3 Sales, 2001-2010
  • Table 4.11: TPA Marker Sensitivity
  • Table 4.12: Worldwide CA-125 Sales, 2001-2010
  • Table 4.13: U.S. CA-125 Sales, 2001-2010
  • Table 4.14: Number of Pap Smears Performed by Country
  • Table 4.15: Lung Cancer Facts
  • Table 4.16: Patient Category Applications
  • Table 4.17: Worldwide AFP Marker Sales, 2001-2010
  • Table 4.18: U.S. AFP Cancer Marker Sales, 2001-2010
  • Table 4.19: Colorectal Cancer Monoclonal Antibody Imaging Kits
  • Table 6.1: Product Sales as a Percent of Total Product Sales
  • Table 6.2: Tumor Diagnosis Immunoassay
  • Table 6.3: Tumor Diagnosis Radioimmunoassay
  • Table 6.4: Summary of Matritech's Product Development Programs
  • Table 6.5: PBM Product List
  • Table 7.1: List and Discounted Prices for Abbott Tumor Marker Tests
  • Table 8.1: CPT Codes for Tumor Markers
  • Table 10.1: Familial Cancer Syndromes and Tumor Suppressor Genes
  • Table 10.2: Oncogenes and Anti-oncogenes
  • Table A3: TNM Classification
  • Table A7: Prevalence of Major Cancers
  • Table A8: Financial Comparison for Moderate and Waived CLIA Labs
  • Table A9: List of Marketers of Occult Blood Diagnostic Test Kits